Evidence map›Paper›PMID 39334963›Full record

ArticleBiomolecules2024

Enhanced Anticancer Activity of 7MeERT over Ertredin: A Comparative Study on Cancer Cell Proliferation and NDUFA12 Binding.

Sonoko Atsumi, Chisato Nosaka, Takefumi Onodera, Hayamitsu Adachi, Takumi Watanabe, Manabu Kawada, Masabumi Shibuya, Se In Park, Ho Jeong Kwon

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sonoko AtsumiInstitute of Microbial Chemistry, Shinagawa-ku, Tokyo 141-0021, Japan.ORCID 0009-0003-7397-7701
Chisato NosakaInstitute of Microbial Chemistry, Shinagawa-ku, Tokyo 141-0021, Japan.
Takefumi OnoderaInstitute of Microbial Chemistry, Shinagawa-ku, Tokyo 141-0021, Japan.
Hayamitsu AdachiInstitute of Microbial Chemistry, Shinagawa-ku, Tokyo 141-0021, Japan.
Takumi WatanabeInstitute of Microbial Chemistry, Shinagawa-ku, Tokyo 141-0021, Japan.
Manabu KawadaInstitute of Microbial Chemistry, Shinagawa-ku, Tokyo 141-0021, Japan.ORCID 0000-0001-9348-4240
Masabumi ShibuyaGakubunkan Institute of Physiology and Medicine, Jobu University, Takasaki-shi, Isesaki 370-1393, Japan.ORCID 0009-0005-9999-6913
Se In ParkChemical Genomics Leader Research Laboratory, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.ORCID 0009-0002-3237-1861
Ho Jeong KwonChemical Genomics Leader Research Laboratory, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.ORCID 0000-0002-6919-833X

Funding

National Research Foundation of Korea 2021R1A3B1077371
6 · The paper itself

Abstract

We have previously identified Ertredin (3-(2-amino-5-bromophenyl) quinoxalin-2(1H)-one) as a compound that suppresses 3D spheroid formation and tumorigenesis in NIH3T3 cells induced by

Indexed as

Antineoplastic AgentsCell ProliferationNADPH DehydrogenaseAnimalsCell Line, TumorElectron Transport Complex IErbB ReceptorsHumansMiceMolecular Docking SimulationProtein BindingAntineoplastic AgentsElectron Transport Complex IErbB ReceptorsNADPH DehydrogenaseNDUFA12 protein, human7MeERTantiproliferative activityErtredinglioblastomaNDUFA12oxidative phosphorylationtumorigenesis

Identifiers

PMID39334963
PMCPMC11430042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.